Invention Grant
US07608271B2 Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group
失效
包含含马来酰亚胺基团的修饰的人免疫缺陷病毒抗融合GP41肽
- Patent Title: Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group
- Patent Title (中): 包含含马来酰亚胺基团的修饰的人免疫缺陷病毒抗融合GP41肽
-
Application No.: US10950010Application Date: 2004-09-24
-
Publication No.: US07608271B2Publication Date: 2009-10-27
- Inventor: Dominique P. Bridon , Robert S. Dufresne , Nisssab Boudjellab , Martin Robitaille , Peter G. Milner
- Applicant: Dominique P. Bridon , Robert S. Dufresne , Nisssab Boudjellab , Martin Robitaille , Peter G. Milner
- Applicant Address: CA Montreal, Quebec
- Assignee: Conjuchem Biotechnologies Inc.
- Current Assignee: Conjuchem Biotechnologies Inc.
- Current Assignee Address: CA Montreal, Quebec
- Agency: Lando & Anastasi, LLP
- Main IPC: A61K39/385
- IPC: A61K39/385 ; A61K39/21
Abstract:
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
Public/Granted literature
- US20050070475A1 Long lasting fusion peptide inhibitors of viral infection Public/Granted day:2005-03-31
Information query
